Dr. Reddy’s Laboratories announces the launch of an authorized generic version of NitroDur(R) (nitroglycerin) Transdermal Infusion System in the U.S. Market 3o5d4l

Business Comments Off on Dr. Reddy’s Laboratories announces the launch of an authorized generic version of NitroDur(R) (nitroglycerin) Transdermal Infusion System in the U.S. Market
Dr. Reddy's Laboratories announces the launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of authorized generic version of NitroDur® (nitroglycerin) Transdermal Infusion System.

The combined market for all Nitrogylcerin Transdermal Patch products had U.S. sales of approximately $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

Dr. Reddy’s Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count.

NitroDur® is a trademark of USpharma Ltd.

Related Articles 2k5c2s

Business

Dr. Reddy’s Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market 1j4r18

Business Comments Off on Dr. Reddy’s Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. May 15, 2019— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Daptomycin […]

Business

Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren(R) Arthritis Pain in the U.S. Market 6n405v

Business Comments Off on Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren(R) Arthritis Pain in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. September 9, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of […]

Business

Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection 3.5 mg/vial 35yr

Business Comments Off on Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection 3.5 mg/vial

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by the U.S. Food […]